| Ulcerative Colitis
Entyvio vs Uceris
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Entyvio vs Uceris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUceris has a higher rate of injection site reactions vs Entyvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uceris but not Entyvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Entyvio
Uceris
At A Glance
IV infusion or SC injection
Every 2 weeks (SC) or every 8 weeks (IV)
alpha4beta7 integrin antagonist
Rectal foam
Twice daily, then once daily
Glucocorticosteroid
Indications
- Ulcerative Colitis
- Crohn Disease
- Ulcerative Colitis
Dosing
Ulcerative Colitis, Crohn Disease Week 0 and Week 2: 300 mg IV infusion over approximately 30 minutes; Week 6 onwards: 300 mg IV infusion every 8 weeks or 108 mg SC injection every 2 weeks; discontinue if no evidence of therapeutic benefit by Week 14.
Ulcerative Colitis 1 metered dose administered rectally twice daily for 2 weeks, followed by 1 metered dose administered rectally once daily for 4 weeks.
Contraindications
- Known serious or severe hypersensitivity reaction to vedolizumab or any excipient (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased heart rate)
- History of known hypersensitivity to budesonide or any ingredient of UCERIS rectal foam, including anaphylaxis
Adverse Reactions
Most common (>=3%) nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities
Serious infusion-related reactions including anaphylaxis, infections (anal abscess, sepsis, tuberculosis, Listeria meningitis, giardiasis, cytomegaloviral colitis), liver injury (elevated transaminases, hepatitis), malignancies
Postmarketing anaphylaxis, acute pancreatitis, interstitial lung disease, pneumonitis
Most common (>=2%) Decreased blood cortisol, adrenal insufficiency, nausea
Serious Hypercorticism and adrenal axis suppression, steroid withdrawal symptoms, increased susceptibility to infection, other glucocorticosteroid effects
Postmarketing Hypertension, pancreatitis, pyrexia, peripheral edema, anaphylactic reactions, dizziness, benign intracranial hypertension, mood swings, pruritus, maculopapular rash, allergic dermatitis
Pharmacology
Vedolizumab is a humanized IgG1 monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibiting the migration of memory T-lymphocytes into inflamed gastrointestinal tissue; the mechanism is gut-selective and does not affect the alpha4beta1 or alphaEbeta7 integrins or VCAM-1 interactions.
Budesonide is a synthetic non-halogenated glucocorticosteroid that exerts local anti-inflammatory activity via glucocorticosteroid receptor binding; it undergoes extensive first-pass hepatic metabolism via CYP3A4, resulting in low systemic bioavailability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Entyvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Uceris
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Entyvio
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Uceris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Entyvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Uceris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Uceris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EntyvioView full Entyvio profile
UcerisView full Uceris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.